“A better system” – managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care
- 1Faculty of Medicine, Health and Life Science, Swansea University, Swansea, Wales, United Kingdom
Abstract
Introduction: The avoidable harm due to incomplete monitoring of repeat prescriptions in primary care has been known for decades, but prevention has proved difficult. We aimed to test the ability of the Adverse Drug Reaction (ADRe) Profile to identify and address clinical problems for patients aged ≥65 prescribed >4 long-term medicines, living in their own homes, and managed in primary care. Methods: A pragmatic cluster-randomized controlled trial was undertaken in 6 primary care practices in South-West Wales, alongside a process evaluation. In addition to usual care, patients in the intervention arm completed the ADRe Profile, which was then shared with the practice pharmacist. Patients completed a second ADRe Profile with the nurse researcher 20 weeks later. The control arm received usual care. Information on patients’ clinical problems and prescriptions was extracted from practice medical records before and after the intervention and analysed using multilevel generalised linear mixed models (GLMM), including practice as a random intercept, and accounting for trial arm, age, deprivation and co-morbidities. Symptoms recorded on the first and second Profiles were compared. Resolution of clinical problems was described, and participants’ perspectives sought. Results: We recruited one general practice group, comprising six practices, and 60 patients. Three patients were lost to the study. Intervention arm patients were more likely to have more than one problem addressed than control arm patients (22/27[82%] vs. 11/30[35%], adjusted odds ratio [aOR] 7.48, 95% confidence interval [CI] 1.99-28.10). All intervention arm patients either benefited or expected to benefit following referrals. For two patients, the intervention proved critical: detection of B12 deficiency in a patient using metformin and flecainide de-prescribing. Fewer patients reported pain by the study’s end (16/27 vs 24/27). All patients were grateful for ADRe, but clinicians had reservations concerning staff time. Conclusion: The ADRe Profile benefited patients by reducing risk of suboptimal prescribing and iatrogenic harm. The project is registered with the Clinicaltrials.gov as NCT04663360 (https://clinicaltrials.gov/study/NCT04663360).
Related
- Selected traditional Chinese medicines for treating amyotrophic lateral sclerosis: a Bayesian network meta-analysis based on randomised controlled trials
- Electroacupuncture with different pulse patterns for the post-acute phase of Bell's palsy: a study protocol for a randomised controlled trial with surface electromyography evaluation.
- Cost-effectiveness of adjunctive hyperbaric oxygen therapy for fibromyalgia: an economic evaluation alongside a single-centre randomised controlled trial in Brazil
- Randomised controlled trial of SHORT duration antibiotic thERapy for critically ill patients with sepsis (SHORTER trial): protocol for a mixed-methods process evaluation
- Evaluation of percutaneous cryoneurotomy compared with surgical open neurotomy for the management of post-stroke spastic equinovarus foot in France: protocol for a multicentre, randomised controlled, open-label, non-inferiority trial
BibTeX
@article{logan2026better,
title = {{“A better system” – managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care}},
author = {Vera Logan and Alex Conboy and Neil Carter and David Hughes and Adam Turner and Alan Watkins and Sue Jordan},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0356480},
url = {https://doi.org/10.1371/journal.pone.0356480},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - “A better system” – managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care
AU - Vera Logan
AU - Alex Conboy
AU - Neil Carter
AU - David Hughes
AU - Adam Turner
AU - Alan Watkins
AU - Sue Jordan
PY - 2026
DA - 2026/09/18
JO - PLOS One
DO - 10.1371/journal.pone.0356480
UR - https://doi.org/10.1371/journal.pone.0356480
AB - Introduction: The avoidable harm due to incomplete monitoring of repeat prescriptions in primary care has been known for decades, but prevention has proved difficult. We aimed to test the ability of the Adverse Drug Reaction (ADRe) Profile to identify and address clinical problems for patients aged ≥65 prescribed >4 long-term medicines, living in their own homes, and managed in primary care. Methods: A pragmatic cluster-randomized controlled trial was undertaken in 6 primary care practices in South-West Wales, alongside a process evaluation. In addition to usual care, patients in the intervention arm completed the ADRe Profile, which was then shared with the practice pharmacist. Patients completed a second ADRe Profile with the nurse researcher 20 weeks later. The control arm received usual care. Information on patients’ clinical problems and prescriptions was extracted from practice medical records before and after the intervention and analysed using multilevel generalised linear mixed models (GLMM), including practice as a random intercept, and accounting for trial arm, age, deprivation and co-morbidities. Symptoms recorded on the first and second Profiles were compared. Resolution of clinical problems was described, and participants’ perspectives sought. Results: We recruited one general practice group, comprising six practices, and 60 patients. Three patients were lost to the study. Intervention arm patients were more likely to have more than one problem addressed than control arm patients (22/27[82%] vs. 11/30[35%], adjusted odds ratio [aOR] 7.48, 95% confidence interval [CI] 1.99-28.10). All intervention arm patients either benefited or expected to benefit following referrals. For two patients, the intervention proved critical: detection of B12 deficiency in a patient using metformin and flecainide de-prescribing. Fewer patients reported pain by the study’s end (16/27 vs 24/27). All patients were grateful for ADRe, but clinicians had reservations concerning staff time. Conclusion: The ADRe Profile benefited patients by reducing risk of suboptimal prescribing and iatrogenic harm. The project is registered with the Clinicaltrials.gov as NCT04663360 (https://clinicaltrials.gov/study/NCT04663360).
SN - 1932-6203
ER -